FDA Advisory Committee recommends approval of Actemra for the treatm..

Scroll de pagina (druk op een toets of muisknop om het scrollen te stoppen) FDA Advisory Committee recommends approval of Actemra for the treatment of rheumatoid arthritis First interleukin-6 inhibitor (IL-6) to offer new therapeutic option for rheumatoid arthritis Roche announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) by a near unanimous (10-1) vote recommended approval of Actemra (tocilizumab), a novel interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody, for reducing the signs and symptoms in adults with moderate to severe rheumatoid arthritis (RA). "We are pleased with the FDA advisory committee's very positive recommendation for Actemra, which helps move this promising new therapy closer to becoming available for patients who suffer from the debilitating symptoms of... [read full story]